Lithium has long been used for the treatment and prophylaxis of bipolar mood disorder. However, nerve cells are not the sole targets of lithium. Indeed, lithium was reported to target numerous cell types, and affect cell proliferation, differentiation and death. Thus, the idea has been raised that lithium may act on signaling pathways involved in neoplastic transformation. Indeed, the effect of lithium on tumor progression is currently being tested in a limited number of clinical trials. However, the molecular mechanisms by which lithium affects neoplastic transformation remain to be characterized. Here, using mouse fibroblasts transformed by the v-src oncogene as a model, we show that lithium drastically inhibits cell motility and compromises the invasive phenotype of v-src-transformed cells. In addition, we show that this effect is mediated by the activation of phosphotyrosine phosphatases, but not by the direct inhibition of the v-Src tyrosine kinase. Finally, we show that lithium activates phosphotyrosine phosphatases by the modulation of the redox status of the cell, independently of the Wnt and the inositol phosphate canonical pathways. Thus, this study supports the idea that lithium, acting similar to an antioxydizer, may have antimetastatic properties in vivo.
Introduction
Lithium is known to target nerve cells and is still being been used for the treatment of nervous disorders (Severus et al., 2008) . However, a multiplicity of cell responses are elicited by lithium outside the nervous system. Indeed, among the other effects, lithium affects embryonic development and tissue patterning (Van Lookeren Campagne et al., 1988; Kao and Elinson, 1989) , promotes the differentiation of epithelial cells, including lens cells (Stump et al., 2006) and increases Ca 2 þ storage in the bone (Clement-Lacroix et al., 2005) . In addition, lithium was described as an inhibitor of the cell cycle (Smits et al., 1999; Mao et al., 2001; Karlovic et al., 2007; Sun et al., 2007) and an accelerator of cell death (Song et al., 2004; Sarkar et al., 2005; Zhang et al., 2005) . Although some of these data may be debatable (Welshons et al., 1995; Ohteki et al., 2000; Wada et al., 2005; Karlovic et al., 2007) , the idea was thus raised that lithium may have antitumor properties (see for example, Edwards et al., 2008; Pizarro et al., 2008) . Actually, its effect on tumor progression is currently being tested in clinical trials (see, http:// clinicaltrials.gov).
At the molecular level, lithium up-or downregulates a large number of genes, illustrating that multiple signaling pathways are affected by lithium treatment (Zhang et al., 2005; Seelan et al., 2008) . Indeed, lithium targets a variety of enzymes, including phosphatases and kinases, involved in phosphatidyl inositol signaling, gluconeogenesis, redox potential, cell proliferation and cell death (reviewed by Gould et al., 2004) .
A number of cell responses elecited by lithium are mediated by the Wnt pathway. Indeed, lithium is capable of inhibiting glycogen synthase kinase-b (GSK-3b), a protein kinase involved in the degradation of b-catenin, thereby mimicking the effects of Wnt signaling activation (Aghdam and Barger, 2007) . Activation of the Wnt pathway stabilizes cytosolic b-catenin, which translocates to the nucleus then stimulates T-cell factor/lymphoid enhancer factor, leading to upregulation of T-cell factor target genes (Reya and Clevers, 2005) . Lithium exerts its inhibitory effect on GSK3b either directly or through activation of the AKT protein kinase (Gould and Manji, 2005) . Importantly, it has recently been reported that the effects of lithium are mediated by a signaling complex containing GSK-3b, AKT and b-arrestin 2, a regulator of G-protein-coupled receptordependent pathways in the brain (Beaulieu et al., 2008) .
The Src family of tyrosine kinases have multiple cellular functions including control of proliferation, survival, motility and adhesion (see review by Benati and Baldari, 2008; Ingley, 2008) . The viral isoforms of these kinases, including p60 v-src , encoded by avian retroviruses, exhibit high transforming capacities (Pessac and Calothy, 1974; Jove et al., 1986; Gillet et al., 1993) , whereas in human, the level of p60 c-src is increased in adenomatous polyps, and is further upregulated during the progression of colon cancer and the development of metastatic disease (Cartwright et al., 1990; Mathew et al., 2008) . In addition, p60
c-src mutations have been found in a small subset of metastatic tumors, although this does not seem to be the predominant mechanism of p60 c-src activation in cancer cells (Johnson and Gallick, 2007) .
Studies over the past 20 years have demonstrated that Src activates multiple signaling pathways depending on cell type. For example, activation of the Ras pathway is essential for cell transformation by v-src in rodent fibroblasts, but not in chick embryo fibroblasts. STAT3 and PI3K have also been described as mediating cell transformation by v-src (Aouacheria et al., 2002 and references therein) . Recent reports have pointed out the ability of Src to upregulate b-catenin expression (Almeida et al., 2005) , suggesting a role for the Wnt/ GSK/b-catenin pathway, and consequently of Wnt regulators, in Src-dependent cell transformation.
Together these data suggest that lithium, which is a potent regulator of the Wnt pathway, may interfere with the mechanisms of cell transformation by the v-src oncogene. Thus, in this study, the effect of lithium was evaluated on v-src-transformed mouse fibroblasts. This led to the finding that lithium treatment resulted in growth inhibition rather than growth activation. In addition, we showed that lithium drastically inhibited the motility and invasion of v-src-transformed cells. Biochemical analyses showed strong inhibition of cellular tyrosine phosphorylation. However, enzyme activity measurements showed that the p60 v-src tyrosine kinase activity itself was not affected by lithium treatment, whereas the activity of phosphotyrosine phosphatases (PTPases) was upregulated. Furthermore, we show that lithium modulates the redox status of the cell, thus activating PTPases, which in turn dephosphorylate cellular phosphotyrosines and block transformation of v-src-expressing cells. Surprisingly enough, these effects were found independent from the Wnt pathway. Finally, this study provides experimental evidence that lithium inhibits v-src-induced cell invasiveness by its antioxydizing properties.
Results

Lithium inhibits cell motility of v-src-transformed cells
To analyse the effect of lithium on v-src-transformed cells, NIH 3T3 mouse cells stably transfected with a vector expressing a thermosensitive form of the p60 v-src kinase (PLNCX-tsLA29) were treated with 5 mM LiCl for 24 h and observed under the light microscope during this time. At permissive temperature (37 1C), the cells exhibited the typical features of neoplastic transformation, including high refringency and motility ( Figure 1A and Supplementary data S1). After lithium treatment, these cells underwent significant morphological changes ( Figure 1A) , as illustrated by a rapid loss of refringency, occurring 4 h after the addition of lithium to the culture medium. Similar changes were observed in different cell lines transformed by the v-src oncogene, including rat and avian fibroblasts (not shown) or nerve cells ( Figure 1B) . However, in NIH 3T3 cells, neither the actin microfilaments nor the microtubule network were significantly altered after lithium treatment (results not shown and Supplementary data S2).
In contrast, lithium had a spectacular effect on podosomes, a form of adhesion structure with an actin core surrounded by a number of adaptor proteins, such as vinculin, that are typical of v-src-expressing fibroblasts (Linder and Kopp, 2005; Oikawa et al., 2008) . Indeed, podosomes totally disappeared after lithium treatment ( Figure 1C and Supplementary data S2); interestingly, these changes occurred together with the inhibition of cell movements, as observed by video timelapse microscopy (Supplementary data S1).
To further analyse the effect of lithium on cell motility, transwell assays were carried out using NIH 3T3 cells treated or not with varying LiCl concentrations. As show in Figure 2a , LiCl inhibited the motility of v-src-transformed NIH3T3 cells in a dose-dependent manner. Motility was significantly reduced at 1 mM LiCl (22% inhibition), and was almost totally abolished at 3 mM LiCl (85% inhibition). The Src inhibitor herbimycin A had a similar effect (90% inhibition). The inhibitory effect of LiCl on cell motility was confirmed by a series of wound assays carried out on v-srctransformed fibroblasts (Figures 2b and c) and epithelial cell lines (Supplementary data S4).
Cell migration was also measured using a transwell assay in the presence of matrigel, which mimicks the extracellular matrix microenvironment. As shown in Figure 3a , v-src-transformed 3T3 cells, in contrast to non-transformed cells, were able to move very efficiently into the matrigel; the MMP-2 proteinase activity detected in v-src-transformed cells possibly contributed to the migration of the cells in this environment (Figure 3b) . The results depicted in Figures 3a and b show that LiCl abolished the migration of v-src-NIH3T3 cells into the extracellular matrigel matrix, and inhibited the MMP-2 proteinase at the same time. Similarly, thermal inactivation of p60 v-src resulted also in MMP-2 inactivation and cell migration arrest. Together, these results indicated that lithium had a potent inhibitory effect on cell migration in vitro.
Effect of lithium on neoplastic transformation
The above observations suggested that lithium was able to counteract the effect of p60 v-src to some extent. Thus, the action of lithium was evaluated on additional features of neoplastic transformation such as cell proliferation rate and growth ability in soft agar. As shown in Figure 4a , LiCl (1-5 mM) moderately affected the growth of NIH3T3 cells on a solid support. As LiCl had no effect on programed cell death under these conditions (not shown), this suggested that cell-cycle progression was not significantly slowed down upon LiCl treatment. In contrast, in the same concentration range, lithium did inhibit colony formation in soft agar in a dose-dependent manner (Figure 4b ), significant inhibition (25%) being already observed at 1 mM.
On this basis, the ability of lithium salts to prevent tumor progression was subsequently evaluated using the chorioallantoic membrane (CAM) assay. In this assay, cells are grafted onto the CAM of chicken eggs and, in the case of v-src-transformed cells, extraembryonic tumors can be observed in less than 2 weeks. As depicted in Figure 5 , v-src-transformed NIH3T3 cells led to rapid tumor development inside the yolk due to the proliferation of grafted cells that had crossed the CAM. However, in the presence of lithium, the development of the tumors was almost totally abolished.
Taken together, the above results indicated that lithium effectively inhibited cell motility in vitro as well as tumor formation, as shown with both in vitro and in vivo assays. Thus, a series of biochemical assays were undertaken to shed light on the underlying molecular mechanisms that were compromised upon LiCl treatment.
Effect of lithium on p60
v-src tyrosine kinase activity First, the effect of lithium on p60
v-src tyrosine kinase activity was analysed. To this end we measured the total phosphotyrosine cell content on whole-protein extracts by western blotting using an antiphosphotyrosine antibody. Figure 6a shows that lithium treatment resulted in a dramatic decrease in the total phosphotyrosine content of v-src-transformed NIH3T3 cells. The same effect was observed using cells transfected with c-Src527 and c-Src416/527, two constitutively active mutants of p60 c-src that lack the regulatory tyrosine at the C-terminus end, and thus exhibit similar specific activity to the viral v-Src isoform (Kmiecik et al., 1988) . Figure 6b shows that paxillin, a scaffold protein interacting with the cytoskeleton and reported as an Src target, is also dephosphorylated after lithium treatment. Similarly, the Src tyrosine kinase inhibitor herbimycin A led to massive paxillin dephosphorylation (Figure 6b ).
To determine whether or not the observed drop of phosphotyrosine cell content was due to a direct effect on the Src tyrosine kinase, the capacity of lithium to inhibit Src kinase activity was evaluated using in vitro phosphorylation assays. The ability of purified recombinant p60 c-src protein to phosphorylate a synthetic peptide, used as a substrate, was quantified by fluorescence emission. Remarkably, as shown in Figure 6c , LiCl had no effect on Src activity under these conditions. This observation was confirmed using another assay that measured the activity of the p60 v-src kinase as immunoprecipitated from whole-cell protein extracts. As shown in Figure 6d , immunoprecipitates from v-src-transfected cells, however much LiCl was present in the culture medium, were able to phosphorylate enolase, a known substrate of the Src tyrosine kinase, contrary to the samples obtained from either non-transfected cells or v-src-transfected cells grown at the non-permissive temperature. Effect of lithium on PTPase activity As massive tyrosine dephosphorylation after lithium treatment was apparently not correlated with the downregulation of p60 v-src kinase activity, this raised the possibility that lithium could be able to activate intracellular PTPases. To address this point, the PTPase activity of a variety of whole-cell protein extracts was quantified in vitro using a fluorescence-based assay. As shown in Figure 7a , in the absence of LiCl, the PTPase activity of total cell protein extracts was low, whether the cells expressed the v-src oncogene or not. This activity was blocked by orthovanadate, a PTPase inhibitor, but not by okadaic acid, an inhibitor of phosphoserine/threonine phosphatases. Interestingly, the extracts from v-src-transfected cells grown in the presence of LiCl showed a dramatic increase of PTPase in a dose-dependent manner, whereas the activity of extracts from non-transfected cells remained low in the presence of LiCl. Of note, orthovanadate but not okadaic acid prevented this activation (Figure 7a ).
On the basis of these observations, we then tested the effect of the PTPase inhibitor orthovanadate on the motility of v-src-transfected cells using the wound assay. As shown in Figure 7b , orthovanadate reduced significantly the LiCl inhibitory effect on cell motility, contrary to okadaic acid. Thus, the specific inhibition of PTPases preserves cell motility in the presence of LiCl. Together, the above results indicated that the activation of intracellular PTPases-but not ser/thr phosphatases-by lithium could mediate its inhibitory effect on cell motility.
The activation of PTPases by lithium is independent of Wnt and IP3 signaling Lithium salts are known to regulate a number of signaling pathways, including the Wnt/b-catenin pathway and the inositol phosphate pathway. We thus investigated if these pathways could be involved in the above cell response elicited by lithium. Surprisingly, we observed that the effect of lithium on cell morphology and motility was not prevented by Quercetin, a potent inhibitor of b-catenin (Park et al., 2005) , suggesting that lithium might inhibit cell motility independently of the Wnt/b-catenin pathway (Supplementary data S5). The activity of the Wnt pathway can be monitored by the nuclear localization of b-catenin. As expected, a number of known activators of the Wnt pathway, including lithium, were found to increase the amount of nuclear b-catenin in v-src-transfected cells (Figures 8a and b) . However, none of the Wnt activators tested were able to reproduce the effect of lithium on the cellular phosphotyrosine content (Figure 8c ), suggesting that PTPases were activated by lithium independently of the Wnt pathway.
Lithium has also been reported to act on the turnover of inositol phosphates; indeed, lithium is an inhibitor of inositol monophosphatase, and leads to a decrease of intracellular inositol triphosphate (IP3) level. The effect of lithium on IP3 level can be counteracted by prolyl endopeptidase inhibitor, an inhibitor of prolyl oligopeptidase activity (Sarkar et al., 2005) . As shown in Figure 8d , L-690,330, a potent inhibitor of IMPase, has no effect on the total phosphotyrosine cell content, whereas prolyl endopeptidase inhibitor was unable to prevent the dephosphorylation of phosphotyrosines after lithium treatment. Together, these data suggest that neither the Wnt pathway nor the IP3 pathway is involved in the activation of PTPases by LiCl.
We have also analysed the effect of Wnt and IP3 regulators on podosomes, whose disappearance after lithium treatment might be a consequence of the massive activation of PTPases. As shown in Figure 8e , none of the Wnt activators had any effect on podosomes, contrary to lithium. Similarly, L-690,330 was also unable to disrupt podosomes, whereas prolyl endopeptidase inhibitor did not prevent lithium effect. Thus, the disruption of podosomes after LiCl treatment seems also independent of Wnt and IP3 signaling.
The effects of lithium on PTPases and cell motility are glutathione-dependent Phosphotyrosine phosphatases are known to be regulated at the post-translational level by their oxidation status. This raised the possibility that lithium could interfere with this regulatory mechanism in v-srctransformed cells, leading to the observed activation of PTPases.
First, an 'in gel' PTPase activity assay, see Markova et al. (2005) , was carried on protein extracts prepared from cells treated or not by LiCl. The results led to the conclusion that the intracellular amount of PTPases was not modified after lithium treatment, suggesting that their activation was due to post-translational modifications (Supplementary data S3) .
Then, we evaluated the effect of reducing and oxidizing agents on the activity of PTPases in v-src- transformed cells. As shown in Figure 9a , the reducing agent b-mercaptoethanol increased the PTPase activity in homogenates from v-src-transformed NIH3T3 cells. In contrast, however, b-mercaptoethanol had no effect on homogenates from cells previously treated with LiCl; indeed, these samples already exhibited maximum activity before the addition of the reducing agent. Conversely, the addition of H 2 O 2 resulted in a dramatic drop of PTPase activity in homogenates from both LiCl-treated and untreated cells (Figure 9a) .
Thus, these data confirmed that redox mechanisms could control the activity of PTPases in v-src-transformed cells and suggested that these regulatory mechanisms could be affected by lithium. Indeed, LiCl was found to increase intracellular glutathione (GSH) levels (Figure 9b) , illustrating that the redox status of the cell is actually modified after lithium treatment.
The above data suggested that the activation of PTPases after LiCl treatment could occur by an increase of intracellular GSH. We thus monitored both GSH concentration and phosphatase activity in v-src-transformed NIH3T3 cells, treated or not with LiCl, in the presence of a reactive oxygen species (ROS) generating system, to prevent the accumulation of GSH. As shown in Figure 10 , the combined actions of the O 2 sulfoximide nor X/XO had significant effect separately. Together, these data indicated that the lowering of intracellular GSH levels by the combined effects of an inhibitor of GSH synthesis and a ROS generating system suppressed the activation of PTPase in v-srctransfected cells after lithium treatment.
Finally, we investigated the effects of these agents on the response to lithium treatment at the cellular level, using the wound assay as a functional read out. The results were in total agreement with the above data, showing that agents that prevented any increase of intracellular GSH level did suppress at the same time the inhibitory effect of LiCl on cell motility (Figure 11 ).
Discussion
In this report, we have analysed the effect of lithium, an inhibitor of GSK-3b and activator of Wnt signaling, on Immunoprecipitates were analysed by western blotting using antiphosphotyrosine antibody; the nitrocellulose membrane was reprobed with antipaxillin for calibration. Cells were grown at 33 1C (except otherwise indicated: 39.5 1C, non-permissive temperature); (Herb): herbimicin (1 mM); (vanadate): inhibitor of PTPases (100 mM); lithium concentrations are indicated. (c) Left: analysis of the effect of lithium on Src tyrosine kinase activity using an in vitro enzymatic assay. The reaction was followed by measuring the fluorescence emitted by the phosphopeptide product. Vertical bars represent emitted fluorescence expressed as a percentage of maximum emission. (neg.): non-phosphorylated peptide substrate (200 mM), used as negative control; (pos.) phosphorylated peptide, used as positive control (200 mM; 100% emission). All reactions were carried out using the same substrate initial concentration (200 mM); a first series of reactions were carried out in the absence of lithium using various concentrations of purified c-Src protein: 1 pM (10% emission), 10 pM (50% emission), 1 nM (95% emission); the effect of lithium (0.1-100 mM) was then evaluated at the concentration of Src protein corresponding to 50% of maximum emission (10 pM), as indicated. (d) Detection of Src activity in immunoprecipitates from 3T3 cells transformed (3T3vSrc) or not (3T3) by v-src; (39.5 1C): cells grown at non-permissive temperature (in these conditions, the v-Src protein is heat-inactivated); (LiCl): cells grown in the presence of 5 mM LiCl; (no): cells grown without LiCl. A specific anti-Src antibody was used for immunoprecipitations. Src kinase activity in immunoprecipitates was detected by measuring their ability to phosphorylate recombinant enolase, a known substrate of v-Src, using g 32 P-labelled ATP. Samples were fractionated by SDSpolyacrylamide gel electrophoresis (PAGE) and the amount of phosphorylated enolase was estimated by autoradiography (top). For calibration purposes, the amount of Src protein present in the immunoprecipitates was evaluated by western blotting with an anti-Src antibody (bottom). cell transformation. Wnt signaling is involved in cell differentiation and maintenance of the epithelial phenotype (Stump et al., 2006) . However, aberrant Wnt activation is observed in many types of cancer, including colon cancer (Reya and Clevers, 2005) . Thus, depending on the intra and extra-cellular context, activators of the Wnt pathway, including GSK-3b inhibitors such as lithium, may either promote or prevent tumor progression.
Using v-src-transformed 3T3 mouse fibroblasts, we show that lithium has a potent antimigratory effect as illustrated by wound assays and cell migration assays (Boyden chambers, ThinCerts, Greiner bio-one, Courtaboeuf, France). In addition, lithium was found to have a similar effect in transformed epithelial cell lines. This latter observation is interesting, as a large number of cancer are of epithelial origin. Moreover, lithium treatment results in disappearance of podosomes and drop of MMP-2 metalloproteinase activity, which may contribute to the inhibition of cell invasivity as observed using matrigel assays. In addition, we show that, while it has a limited effect on cell proliferation, lithium efficiently prevents the formation of colonies in soft agar as well as the growth of experimental tumors from v-src-transformed cells grafted on chicken egg CAM.
At a molecular level, a first possibility could have been that the effect of lithium on v-src-transformed cells was merely due to the direct inhibition of the p60 v-src kinase itself. Indeed, LiCl was previously reported to lead to the dephosphorylation of the Y416 residue of the p60 c-src kinase and was thus proposed to be an inhibitor of p60 c-src (Hashimoto et al., 2003) . Actually, the activity of p60 c-src largely depends on the phosphorylation status of Y416 (reviewed by Roskoski, 2004) . We report here that the LiCl treatment leads to the dephosphorylation of the Y416 residue of the p60 v-src kinase as well. However, contrary to p60 c-src , the p60 v-src kinase (or alternatively activated p60
c-src , devoid of Y527 at the Cterminus) is moderately affected by the phosphorylation of Y416 (Cross and Hanafusa, 1983; Kmiecik et al., 1988; Schindler et al., 1999) . Our observations confirmed these previous data; indeed, it is shown here that NIH 3T3 cells expressing either p60
(devoid of Y527) or the p60 c-src double mutant (devoid of both Y416 and Y527) do have similar phosphotyrosine contents, confirming that the phosphorylation level of Y416 is not an indication of p60 v-src kinase activity (Figure 6a) .
Moreover, our observations suggest that the decrease of total phosphotyrosine cell content, observed after treatment of v-src-transformed 3T3 cells with LiCl, might not be the consequence of a decrease in p60 v-src kinase activity. Indeed, in vitro enzymatic assays as well as kinase assays carried out on immunoprecipitates from cell lysates confirmed that LiCl did not significantly alter p60 v-src kinase activity. In contrast, this study supports the idea that lithium inhibits neoplastic transformation by an increase in intracellular glutathione, which in turn stimulates PTPase activity. Thus, the reversion of the transformed phenotype after lithium treatment, including disruption of podosomes and drop of MMP-2 proteinase activity, could be the consequence of the dephosphorylation of a number of p60 v-src substrates by PTPases. Interestingly, lithium has been reported previously to activate Figure 9 A possible interplay between lithium, cell redox status and PTPase activity. (a) Effect of b-mercaptoethanol (BME) and H 2 O 2 on PTPase activity. PTPase activity was quantified on whole-cell protein extracts using a fluorescent-based assay. Cells were grown with LiCl or NaCl. BME and H 2 O 2 were added to the reaction mix at the indicated concentrations. (b) Effect of lithium on GSH intracellular concentration. GSH was quantified from whole-cell extracts by a fluorescent-based assay. Vertical bars represent GSH concentrations.
membrane bound PTPases in rat brain (Zhen et al., 2002) . In addition, it was recently shown to activate the expression of glutamate-cysteine ligase-an enzyme of the glutathione synthesis pathway-in rat cerebral cortical cells and human neuroblastoma cells (Cui et al., 2007) , suggesting that, in the brain, LiCl may also regulate PTPases by glutathione. This idea is further supported by numerous reports indicating that the activity of intracellular PTPases is regulated by their redox status (reviewed by Pao et al., 2007) . The precise identification of the PTPases that are activated upon LiCl treatment in v-src-transformed cells and the characterization of the molecular link between LiCl and GSH content in these cells are important issues to be addressed.
However, although the activation of PTPases as a consequence of the increase of intracellular GSH appear to play a central role in the reversion of the transformed phenotype by dephosphorylating a number of p60 v-src targets, GSH may also directly influence cell migration by preventing ROS accumulation. Indeed, a number of reports suggest that ROS are able to increase cell motility by acting on the actin cytoskeleton dynamics and RAC-1 activity (see for example, Moldovan et al., 2000 Moldovan et al., , 2006 .
The exact mechanisms by which lithium leads to the increase of GSH and subsequent PTPase activation are not known. Surprisingly, the Wnt pathway, a known target of lithium, does not seem to participate in the cell response described herein. Indeed, the b-catenin inhibitor quercetin is unable to prevent the inhibitory effect of lithium on cell motility (Supplementary data S5) . Moreover, although the Wnt pathway is actually activated by lithium in v-src-transformed 3T3 cells, as illustrated by the translocation of b-catenin into the nucleus, other Wnt activators, such as inhibitors VII and VIII, SB and Wnt-3a, have no effect on GSH content, PTPase activity or cell motility (not shown, see also Figure 8) . Similarly, the IP3 pathway, another important target of lithium, does not seem to mediate the inhibitory effect of lithium on cell motility.
Taken together, our results indicate that neither the Wnt pathway nor the IP3 pathway are involved in the cell response to lithium treatment described herein, although these two major signaling pathways are acknowledged targets of lithium (Gould et al., 2004; Zhang et al., 2005) . In contrast, our results suggest that the effect of lithium on the motility of v-src-transformed cells is mainly mediated by modifications of the intracellular redox status. Thus, the possibility exists that a number of previously described effects of lithium could be, at least partly, mediated by this alternative mechanism. In this respect, microarray profiling of lithium-regulated genes revealed that lithium activated the expression of a number of genes which may contribute to the cell response described herein, including the tyrosine phosphatase PTPRK and the antioxydant peroxiredoxin (Seelan et al., 2008) .
Finally, although lithium exhibits significant toxicity at doses above 1.5 mM in humans, the fact that it does not significantly affect PTPase activity in non-transformed cells, as shown in this report (Figure 7a ), suggests that it may preferentially affect tumor cells, and have effective antimetastatic properties in vivo. Of note, the effects of lithium on cell motility and colony formation are already significant at concentrations close to 1 mM, a value that might be compatible with a therapeutic use. Actually, as already mentioned, the antitumor effect of lithium is currently being tested in clinical trials. Another interesting point raised by this study relates to the antioxidant effect of lithium that may help dampen oxidative stress, and protect against the deleterious effects of ionizing radiations in radiotherapy. Additional studies on appropriate animal models will be undertaken shortly to address these points.
Materials and methods
Cell lines and culture conditions NIH3T3 cells stably transfected with PLNCX-tsLA29 or empty plasmid (Maroney et al., 1992) were maintained in Dulbecco's modified Eagle's Medium (Invitrogen, Cergy-Pontoise, France, Cat no. 41965-039) Supplemented with 10 mg/ml streptomycin, 66 mg/ml penicillin and 10% (v/v) and 10% fetal calf serum (FCS, PAA) under 5% CO 2 at 37 1C and G418 (200 mg/ml, GIBCO). Quail neuroretina cells were grown in b-mercaptoethanol (GIBCO) as described in Aouacheria et al. (2002) . Cells were treated with the ROS generators buthionine sulfoximide and X/XO as described in Almeida et al. (2003) and Yang et al. (2003) .
Reagents and antibodies
See Supplementary data S6.
Western blot, immunoprecipitation, immunofluorescence These assays were carried out using the standard protocols (see Supplementary data S6).
In vitro migration and invasion assay Equal numbers of cells (1 Â 10 5 ) in Dulbecco's modified Eagle's medium complemented with 2% FCS were added to the upper compartment of the chamber (ThinCerts, 12 wells, 8 mm, translucent, Greiner bio-one, Courtaboeuf, France) and kept at 37 1C for 16 h. As a chemoattractant, the lower compartment contained Dulbecco's modified Eagle's medium supplemented with 10% FCS. At the end of the incubation period, cells from the upper surface of the filter were wiped off with a cotton swab. The lower surface of the filter was stained with DiffQuick (Dade Behring, Zurich, Switzerland). The number of cells having migrated to the bottom of the chamber was counted in the light microscope on 10 randomly selected fields. The mean number of cells was calculated per field. Three sets of experiments were carried out, each in triplicate. For the matrigel assay, the filter was replaced by a BD BioCoat Matrigel invasion chamber (BD Bioscience, le Pont de Claix, France).
Wound assay and cell proliferation assay These assays were carried out using standard protocols, see Supplementary data S6.
Gelatin zymography assay Cells were pre-cultured in the medium with 2% FCS under different conditions for 24 h at the same density (2 Â 10 5 cells per cm 2 ). The conditioned medium was then assayed for gelatinase activity by gelatin zymography assay as described in Ronziere et al. (2003) . Briefly, the conditioned medium was mixed with Laemmli buffer in a 12% SDS-polyacrylamide gel electrophoresis containing 1 mg/ml gelatin (Sigma, St Quentin Fallavier, France). After electrophoresis at 200 V for 1 h, the gel was washed twice in a 2.5% Triton X-100 solution, for 30 min. The gel was then incubated in buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM CaCl 2 , 1 mM ZnCl 2 , 1% Triton X-100 and 0.02% NaN 3 for 24 h in a 37 1C water bath, after which the gel was stained with 0.5% Coomassie blue in 30% methanol and 10% acetic acid.
CAM assay
Fertilized chick eggs were incubated in a constant humidity egg breeder at 37 1C. On the third day of incubation, the air chamber of the egg was aspirated, to detach the developing CAM from the shell. A 1% agar cube containing 10 mM of LiCl or NaCl was loaded with 10 6 cells on the CAM through a 1 cm 2 shell window. After 10 days of incubation in the humidified egg breeder without tilt, tumor growth was analysed using a LUMAR fluorescent stereomicroscope (Zeiss, le Pecq, France).
Measurement of colony formation in soft agar
Cells were cultured under different conditions for 24 h. A total of 10 5 Trypan blue-negative cells were re-suspended in 1 ml of Earle's balanced salt solution medium supplemented with 20% FCS, containing 0.18% agarose. Re-suspended cells were then plated onto six-well culture dishes coated with Earle's balanced salt solution medium containing 20% FCS and 0.5% agarose. Cells were maintained for 3-4 weeks at 36.5 1C and the culture medium was renewed (2 ml Earle's balanced salt solution, 20% FCS) every second day. Samples were analysed for colony formation 3 weeks later. Three independent experiments, each in triplicate, were performed.
Enzymatic assays
See Supplementaruy data (S6) for a description of Src and PTPase activity.
GSH assay
Intracellular GSH concentration was measured according to the manufacturer's protocol (Millipore, Molsheim, France, Cat no. APT 250).
